New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.» Read More
Investors are loading up on stocks, TD Ameritrade CEO Fred Tomczyk says.
The "Fast Money" traders share their final trades.
U.S. regulators dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.
The Forensic Accounting ETF launches today. The fund spotlights a concept that is often woefully overlooked.
U.S. stock index futures continued to trade mixed Thursday despite a better-than-expected jobless claims report, as disappointing Apple earnings weighed on technology stocks.
A flood of earnings reports, including major technology and industrial companies, could make or break the stock market’s surprise January rally in the week ahead.
Jim Cramer’s researcher Nicole Urken reviews the potential biotech pipeline winners there were highlighted this week on Mad Money.
Goldman Sachs strategists have issued a big warning to clients hiding out in bond funds: You're about to lose your shirt.
Some of the names on the move ahead of the open.
The current weakness in the yen is bad news for U.S. companies competing with Japanese counterparts.
Cramer makes the call on viewer favorites.
Here are Wednesday's morning movers.
Check out which companies are making headlines after the bell Tuesday:
Three of the top ten dividend stocks in the S&P are drug stocks. Will they lose out if dividend taxes rise?
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
*DOJ, SEC convinced enforcement changing corporate culture. At least eight of the world's top 10 drugmakers, including Bristol-Myers Squibb Co, Pfizer Inc and Johnson&, have disclosed U.S. probes under the 1977 Foreign Corrupt Practices Act.
TRENTON, N.J.-- Pfizer Inc., the world's biggest drugmaker by revenue, will focus on progress on key experimental drugs, recent drug approvals and its ongoing corporate makeover when it reports third-quarter results before the stock market opens Tuesday.
WASHINGTON, Oct 25- Boehringer Ingelheim Pharmaceuticals Inc agreed to pay $95 million to U.S. government agencies to settle civil allegations that it illegally marketed drugs for unapproved uses, the U.S. Justice Department said on T hur sday.
*Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. *Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.
*Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.